Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
MedPage Today on MSN2d
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without DiabetesThe number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...
The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
This article is part of a special series investigating the GLP-1 agonist boom. Read more here. A growing number of studies show that semaglutide seems to have many beneficial effects in addition ...
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating his fluid retention with 100 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback